Sex‐ and Gender‐Based Reporting in Antihypertensive Medication Literature Informing Hypertension Guidelines

Author:

Gulamhusein Nabilah12ORCID,Turino Miranda Keila3ORCID,Dumanski Sandra M.1245ORCID,González Bedat María Carlota6ORCID,Ulasi Ifeoma7ORCID,Conjeevaram Arvind8ORCID,Ahmed Sofia B.149ORCID

Affiliation:

1. Cumming School of Medicine University of Calgary Calgary Alberta Canada

2. Libin Cardiovascular Institute University of Calgary Calgary Alberta Canada

3. Department of Kinesiology and Physical Education McGill University Montreal Quebec Canada

4. Alberta Kidney Disease Network Calgary Alberta Canada

5. O’Brien Institute for Public Health Calgary Alberta Canada

6. Uruguayan Dialysis Registry and Latin American Dialysis and Renal Transplantation Registry Montevideo Uruguay

7. University of Nigeria Nsukka Enugu State Nigeria

8. The Bangalore, Sagar and Trustwell Hospitals Bengaluru Karnataka India

9. Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta Canada

Abstract

Background Hypertension is the leading modifiable cardiovascular risk factor with recognized sex‐ and gender‐based differences. We assessed the incorporation of sex and gender reporting in the antihypertensive medication literature informing hypertension guidelines. Methods and Results Literature cited in the International Society of Hypertension (2020), European Society of Cardiology/European Society of Hypertension (2018), American College of Cardiology/American Heart Association (2017), Latin American Society of Hypertension (2017), Pan‐African Society of Cardiology (2020), and Hypertension Canada (2020) guidelines was systematically reviewed. Observational studies, randomized controlled trials, and systematic reviews involving antihypertensive medications were included. Studies with participants of a single sex, guidelines, and commentaries were excluded. Data on study participation‐to‐prevalence ratio by sex, analysis of baseline demographics and study outcomes by sex, and stratification of adverse events by sex were extracted. Of 1659 unique citations, 331 studies met inclusion criteria. Of those, 81% reported the sex of participants, and 22% reported a male‐to‐female participation‐to‐prevalence ratio of 0.8 to 1.2. Three percent of studies stratified baseline characteristics by sex, and 20% considered sex during analysis through statistical adjustment or stratification. Although 32% of studies reported adverse events, only 0.6% stratified adverse events by sex. Most (58%) studies reporting sex/gender used sex and gender terms interchangeably. Conclusions Incorporation of sex‐ and gender‐based considerations in study population, analysis, or reporting of results and adverse events is not common in the antihypertensive medication literature informing international hypertension guidelines. Greater attention to sex‐ and gender‐based factors in research is required to optimally inform management of hypertension.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference58 articles.

1. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

2. High Blood Pressure and Cardiovascular Disease

3. Sex-specific differences in hypertension and associated cardiovascular disease

4. Global report on hypertension: the race against a silent killer. Accessed September 23 2023. https://www.who.int/teams/noncommunicable‐diseases/hypertension‐report.

5. World health organization: hypertension. 2023. Accessed September 23 2023. https://www.who.int/news‐room/fact‐sheets/detail/hypertension.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3